These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 19680292)
1. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T; Liu G; Tsao MS Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292 [TBL] [Abstract][Full Text] [Related]
2. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Hirsch FR Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291 [TBL] [Abstract][Full Text] [Related]
3. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281 [TBL] [Abstract][Full Text] [Related]
5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
6. EGFR FISH versus mutation: different tests, different end-points. Cappuzzo F Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287 [TBL] [Abstract][Full Text] [Related]
7. EGFR inhibitors: what have we learned from the treatment of lung cancer? Giaccone G; Rodriguez JA Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096 [TBL] [Abstract][Full Text] [Related]
8. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Wong KK Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. Eberhard DA; Giaccone G; Johnson BE; J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673 [TBL] [Abstract][Full Text] [Related]
11. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. da Cunha Santos G; Saieg MA; Geddie W; Leighl N Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669 [TBL] [Abstract][Full Text] [Related]
13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Bunn PA; Thatcher N Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768 [TBL] [Abstract][Full Text] [Related]
14. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819 [TBL] [Abstract][Full Text] [Related]
15. Impact of EGFR mutation analysis in non-small cell lung cancer. Yamamoto H; Toyooka S; Mitsudomi T Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859 [TBL] [Abstract][Full Text] [Related]
16. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Batus M; Fidler MJ; Bonomi PD Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630 [TBL] [Abstract][Full Text] [Related]
19. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959 [TBL] [Abstract][Full Text] [Related]
20. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Ray M; Salgia R; Vokes EE Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]